TY - JOUR
T1 - Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients
AU - Coller, Janet
AU - Michalakas, Jennifer
AU - James, Heather
AU - Farquharson, Aaron
AU - Colvill, Joel
AU - White, Jason
AU - Somogyi, Andrew
PY - 2012/11
Y1 - 2012/11
N2 - AIMS To compare the O- (CYP2D6 mediated) and N- (CYP3A4 mediated) demethylation metabolism of tramadol between methadone and buprenorphine maintained CYP2D6 extensive metabolizer subjects. METHODS Nine methadone and seven buprenorphine maintained subjects received a single 100mg dose of tramadol hydrochloride. Blood was collected at 4h and assayed for tramadol, methadone, buprenorphine and norbuprenorphine (where appropriate) and all urine over 4h was assayed for tramadol and its M1 and M2 metabolites. RESULTS The urinary metabolic ratio [median (range)] for O-demethylation (M1) was significantly lower (P= 0.0002, probability score 1.0) in the subjects taking methadone [0.071 (0.012-0.103)] compared with those taking buprenorphine [0.192 (0.108-0.392)], but there was no significant difference (P= 0.21, probability score 0.69) in N-demethylation (M2). The percentage of dose [median (range)] recovered as M1 was significantly lower in subjects taking methadone compared with buprenorphine (0.069 (0.044-0.093) and 0.126 (0.069-0.187), respectively, P= 0.04, probability score 0.19), M2 was significantly higher in subjects taking methadone compared with buprenorphine (0.048 (0.033-0.085) and 0.033 (0.014-0.049), respectively, P= 0.04, probability score 0.81). Tramadol was similar (0.901 (0.635-1.30) and 0.685 (0.347-1.04), respectively, P= 0.35, probability score 0.65). CONCLUSIONS Methadone inhibited the CYP2D6-mediated metabolism of tramadol to M1. Hence, as the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol.
AB - AIMS To compare the O- (CYP2D6 mediated) and N- (CYP3A4 mediated) demethylation metabolism of tramadol between methadone and buprenorphine maintained CYP2D6 extensive metabolizer subjects. METHODS Nine methadone and seven buprenorphine maintained subjects received a single 100mg dose of tramadol hydrochloride. Blood was collected at 4h and assayed for tramadol, methadone, buprenorphine and norbuprenorphine (where appropriate) and all urine over 4h was assayed for tramadol and its M1 and M2 metabolites. RESULTS The urinary metabolic ratio [median (range)] for O-demethylation (M1) was significantly lower (P= 0.0002, probability score 1.0) in the subjects taking methadone [0.071 (0.012-0.103)] compared with those taking buprenorphine [0.192 (0.108-0.392)], but there was no significant difference (P= 0.21, probability score 0.69) in N-demethylation (M2). The percentage of dose [median (range)] recovered as M1 was significantly lower in subjects taking methadone compared with buprenorphine (0.069 (0.044-0.093) and 0.126 (0.069-0.187), respectively, P= 0.04, probability score 0.19), M2 was significantly higher in subjects taking methadone compared with buprenorphine (0.048 (0.033-0.085) and 0.033 (0.014-0.049), respectively, P= 0.04, probability score 0.81). Tramadol was similar (0.901 (0.635-1.30) and 0.685 (0.347-1.04), respectively, P= 0.35, probability score 0.65). CONCLUSIONS Methadone inhibited the CYP2D6-mediated metabolism of tramadol to M1. Hence, as the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol.
KW - Buprenorphine
KW - CYP2D6 inhibition
KW - In vivo
KW - Methadone
KW - Tramadol metabolism
UR - http://www.scopus.com/record/display.url?eid=2-s2.0-84867353093&origin=inward&txGid=0A11D266DD866450D259226F2DF929AB.euC1gMODexYlPkQec4u1Q%3a299
UR - http://www.scopus.com/inward/record.url?scp=84867353093&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2125.2012.04256.x
DO - 10.1111/j.1365-2125.2012.04256.x
M3 - Article
SN - 0306-5251
VL - 74
SP - 835
EP - 841
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 5
ER -